hlaAllele	source	sourceEvent	sourceUrls	studyNctId	studyTitle	countriesOfStudy	treatment	sourceRelevantTreatmentApproaches	relevantTreatmentApproaches	applicableCancerType	applicableDoid	blacklistCancerTypes	level	direction	evidenceUrls
A*02	CKB_EVIDENCE	A*02	http				Nivolumab			All cancer types	X	Hematologic cancer;2531	A	RESPONSIVE	http
A*02	CKB_TRIAL	A*02	http	NCT1	study1	Netherlands	Nivolumab			Skin melanoma	X	Hematologic cancer;2531	A	RESPONSIVE	http